  | GUREGHIAN, V., HERBST, H., KOZAR, I., MIHAJLOVIC, K., Malod-Dognin, N., Ceddia, G., ANGELI, C., WURTH-MARGUE, C., RANDIC, T., PHILIPPIDOU, D., TETSI NOMIGNI, M., HEMEDAN, A., TRANCHEVENT, L.-C., LONGWORTH, J., Bauer, M., BADKAS, A., GAIGNEAUX, A., Muller, A., OSTASZEWSKI, M., ... KREIS, S. (October 2023). A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma. Cancer Gene Therapy, 30 (10), 1330 - 1345. doi:10.1038/s41417-023-00640-z  Peer Reviewed verified by ORBi |
 | Randic, T., Kozar, I., Margue, C., Utikal, J., & Kreis, S. (29 May 2021). NRAS mutant melanoma: Towards better therapies. Cancer Treatment Reviews, 99. doi:10.1016/j.ctrv.2021.102238 Peer Reviewed verified by ORBi |
 | Kozar, I., Philippidou, D., Margue, C., Gay, L., Renne, R., & Kreis, S. (2021). Cross-Linking Ligation and Sequencing of Hybrids (qCLASH) Reveals an Unpredicted miRNA Targetome in Melanoma Cells. Cancers. doi:10.3390/cancers13051096 Peer Reviewed verified by ORBi |
  | Kozar, I. (2020). From drug resistance mechanisms to microRNA function in melanoma [Doctoral thesis, Unilu - University of Luxembourg]. ORBilu-University of Luxembourg. https://orbilu.uni.lu/handle/10993/43062 |
 | Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S. (15 February 2019). Many ways to resistance: How melanoma cells evade targeted therapies. Biochimica et Biophysica Acta - Reviews on Cancer, 1871 (2), 313-322. doi:10.1016/j.bbcan.2019.02.002 Peer Reviewed verified by ORBi |
 | Margue, C., Philippidou, D., Kozar, I., Cesi, G., Felten, P., Kulms, D., Letellier, E., Haan, C., & Kreis, S. (February 2019). Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells. Journal of Experimental and Clinical Cancer Research, 38 (1). doi:10.1186/s13046-019-1038-x Peer Reviewed verified by ORBi |
 | Cesi, G., Philippidou, D., Kozar, I., Kim, Y. J., Bernardin, F., Van Niel, G., Wienecke-Baldacchino, A., Felten, P., Letellier, E., Dengler, S., Nashan, D., Haan, C., & Kreis, S. (2018). A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells. Molecular Cancer, (17:145). doi:10.1186/s12943-018-0886-x Peer Reviewed verified by ORBi |
 | Kreis, S., Kozar, I., Cesi, G., Margue, C., & Philippidou, D. (2017). Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. Biochimica et Biophysica Acta. doi:10.1016/j.bbagen.2017.04.005 Peer reviewed |
 | Rolvering, C., Zimmer, A., Kozar, I., Hermanns, Letellier, E., Vallar, L., Nazarov, P., Nicot, N., Ginolhac, A., Haan, S., Behrmann, I., & Haan, C. (2017). Crosstalk between different family members: IL27 recapitulates IFNγ responses in HCC cells, but is inhibited by IL6-type cytokines. BBA Molecular Cell Research, 516-526. doi:10.1016/J.BBAMCR.2016.12.006 Peer Reviewed verified by ORBi |
 | Zimmer, A. D., Walbrecq, G., Kozar, I., Behrmann, I., & Haan, C. (2016). Phosphorylation of the PDH complex precedes HIF-1-mediated effects and PDK1 upregulation during the first hours of hypoxic treatment in HCC cells. Hypoxia, 4, 135-145. doi:10.2147/HP.S99044 Peer reviewed |